Market Overview
The Japan apheresis market reached US$ XX million in 2025 and is expected to reach US$ XX million by 2033, growing at a CAGR of XX% during the forecast period 2026-2033.
Apheresis is a process of removal of whole blood from a donor or a patient which is then centrifuged to separate the blood components such as platelets, plasma, red blood cells (RBCs), and white blood cells (WBCs). After the separation the desired component is retained and the rest is retransfused back to the donor. The principle of separation behind the apheresis is centrifugation, where the components get separated based on their density. Apheresis is performed for donated blood and also plays a vital role in several therapies such as the treatment of leukemia, sickle cell anemia, auto-immune disorders, and several neurological conditions.
Market Scope
| Metrics | Details |
| CAGR | XX% |
| Market Size | 2023-2033 |
| Market Estimation Forecast Period | 2026-2033 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Product Type, Technology, Procedure, Application and End-User |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics: Drivers
Rising initiatives by major market players in Japan
Several manufacturers who are leading in these technologies, also based in Japan have taken initiatives such as conducting educational sessions and offering hands-on training services across Japan. These initiatives aim at employing apheresis technology in manufacturing as well as clinical settings and are expected to boost the market growth in the forecast period.
One of the leading players in apheresis technology, Asahi Kasei Corporation. as a part of its R&D program has been offering training for therapeutic apheresis in its facility called the Apheresis Technology Square (the A-Square). This center provides hands-on training with the latest information on therapeutic apheresis to healthcare professionals all across Japan and the world.
Segment Analysis
The Japan apheresis market is segmented based on product type, technology, end-users and region.
The membrane filtration in the technology segment accounted for approximately 43.5% of the Japan apheresis market share
Initially, the apheresis technology in Japan was adopted from the U.S. and is based on the centrifugation process. With the advent of technology, many major players who are specialized in manufacturing apheresis devices have come up with technologies that deviate from centrifugation. The apheresis technology that is quite popular in Japan currently is membrane filtration. The therapeutic apheresis in Japan is majorly based on this technique. The Japanese society even formed special guidelines to be followed during the procedure taking into consideration the membrane filtration technology. Moreover, the Japan-based companies that play a key role in the apheresis market offer products based on membrane filtration technology.
Key Developments
December 2025: Terumo Corporation launched its latest automated plasma apheresis system in Japan, designed for improved efficiency in hematology and immunology treatments, supported by a ¥7.8 billion upgrade of manufacturing infrastructure and expanded clinical roll‑out across major hospitals to boost throughput and procedural safety. The platform integrates advanced process control and real‑time monitoring features tailored to Japan’s aging‑population‑driven demand for therapeutic plasma exchange.
November 2025: Kawasumi Laboratories completed the acquisition of a domestic biomedical equipment supplier to strengthen its apheresis device portfolio, using a ¥4.3 billion investment to integrate advanced filtration technologies for therapeutic plasma exchange and consolidate its position in Japan’s hospital‑centric apheresis market.
October 2025: Asahi Kasei Medical introduced next‑generation leukocyte and platelet apheresis filters specifically for oncology and autoimmune disease management in Japan, committing ¥5.1 billion to R&D and regulatory approvals to accelerate nationwide deployment and improve clinical outcomes in complex blood‑component procedures.
Competitive Landscape
The major players in the apheresis market include Asahi Kasei Medical Co., Ltd., SB-KAWASUMI LABORATORIES, INC., Terumo Corporation, KANEKA CORPORATION, Otsuka Medical Devices Co., Ltd., Nikkiso Co., Ltd., Haemonetics Corporation, and B. Braun SE among others.
Why Purchase the Report?
- To visualize the Japan apheresis market segmentation based on product type, technology, procedure, applications, end users as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of apheresis market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The Japan apheresis market report would provide approximately 39 tables, 34 figures, and 187 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
